Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first…
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in…
Read More...
Read More...
